Strong alliance! Development cooperation of bispecific antibody between Yaoming biology and Zhengda Tianqing

January 2, 2019 / Meitong news agency / -- Yaoming biology and Zhengda Tianqing, the world's leading open biopharmaceutical technology platform company, announced that they had reached cooperation on the development of an innovative bispecific antibody According to the agreement, Zhengda Tianqing is authorized to use the dual specific antibody technology platform wuxibody with independent intellectual property rights of YaoMing biology Gamma Develop an innovative bispecific antibody, and provide technical support for the discovery, development and production of the product Both sides will make full use of their respective advantages and resources to carry out cooperation and achieve win-win cooperation in the field of biomedical research and development As a bispecific antibody technology platform with independent intellectual property rights, wuxibody Gamma It has broken through the technical bottleneck of most bispecific antibody platforms, effectively overcome the challenges of low expression, high polymer and low purification yield in the development process of bispecific antibodies, and has the advantages of saving 6 to 18 months of R & D time for each project and significantly reducing the production cost of bispecific antibodies, which is expected to become one of the best bispecific antibody platforms in the industry Since its global debut, the platform has reached cooperation agreements with six domestic and foreign companies in just three months, enabling partners to layout a new generation of antibody therapy, benefiting patients around the world About wuxibody Gamma WuXiBody Gamma It is a bispecific antibody technology platform with independent intellectual property rights, and is expected to become one of the best bispecific antibody platforms in the industry This platform has broken through the technical bottleneck of most bispecific antibody platforms, effectively overcome the challenges of low expression, high polymer and low purification yield in the development process of bispecific antibodies, and has the advantages of saving 6-18 months of R & D time for each project and significantly reducing the production cost of bispecific antibodies At present, the expression of bispecific antibody is up to 16g / L, and the purity and yield of purified protein A are over 95% Meanwhile, wuxibody Gamma The platform also has unique flexibility to build a variety of valence numbers (such as bivalent, trivalent or tetravalent bispecific antibodies) and structures to meet the biological characteristics of different projects About Zhengda Tianqing Zhengda Tianqing Pharmaceutical Group is an innovative pharmaceutical group enterprise integrating scientific research, production and sales It is a well-known domestic research and development and production base of liver health drugs It is a key high-tech enterprise of the state and a key backbone enterprise of Lianyungang new pharmaceutical industry base of the national torch plan In 2017, it ranked 17th in the list of top 100 pharmaceutical enterprises in China With the development of enterprises and the improvement of R & D capability, the annual R & D cost of Zhengda Tianqing has exceeded 1 billion yuan At present, Zhengda Tianqing has more than 1000 R & D personnel and more than 180 research projects, including more than 30 first-class new drugs and more than 20 biological drugs As a Hong Kong listed company, Yaoming bio pharmaceutical is the world's leading open and integrated platform for biopharmaceutical capability and technology enabling The company provides a full range of end-to-end R & D services for global biopharmaceutical companies and biotechnology companies, helps anyone and any company to discover, develop and produce biopharmaceuticals, realizes the whole process from concept to commercial production, accelerates the global R & D process of biopharmaceuticals, reduces the cost of research and development, and benefits patients As of June 30, 2018, 187 comprehensive projects have been developed on the platform, including 98 in the preclinical research stage, 78 in the early clinical stage (phase I, phase II), 10 in the late clinical stage (phase III) and 1 in the commercial production stage It is estimated that by 2021, the total capacity of the company's planned biopharmaceutical production bases in China, Ireland, Singapore and the United States will be about 220000 liters, which will effectively ensure that the company will provide customers with biopharmaceuticals that meet global quality standards through a sound and strong global supply chain network.